- Report
- March 2024
- 189 Pages
Global
From €3263EUR$3,374USD£2,796GBP
€3625EUR$3,749USD£3,107GBP
- Report
- April 2024
- 93 Pages
Global
From €5415EUR$5,600USD£4,641GBP
- Report
- January 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,144GBP
- Report
- October 2023
- 229 Pages
Global
From €5318EUR$5,499USD£4,558GBP
- Report
- October 2018
- 65 Pages
Global
From €5754EUR$5,950USD£4,931GBP
- Report
- January 2022
- 200 Pages
Global
From €7253EUR$7,500USD£6,216GBP
- Report
- January 2022
- 60 Pages
Global
From €3820EUR$3,950USD£3,274GBP
- Report
- August 2021
Europe
From €3307EUR$3,420USD£2,834GBP
- Report
- August 2021
Global
From €3859EUR$3,990USD£3,307GBP
- Report
- February 2024
- 86 Pages
Global
From €3500EUR$3,877USD£3,105GBP
- Report
- June 2022
- 131 Pages
Global
From €1934EUR$2,000USD£1,658GBP
- Drug Pipelines
- September 2020
- 140 Pages
Global
From €1934EUR$2,000USD£1,658GBP
The Paroxysmal Nocturnal Hemoglobinuria (PNH) drug market is a specialized segment within the broader category of hematological drugs, which encompasses medications for a wide range of blood disorders. PNH is a rare, life-threatening blood disease characterized by the destruction of red blood cells, leading to hemoglobin release in the urine, particularly noticeable at night or in the early morning. Treatments for PNH focus on reducing hemolysis, preventing thrombosis, and improving quality of life. Historically, the management of PNH involved supportive treatments such as blood transfusions and iron therapy; however, the advent of novel targeted therapies has transformed the therapeutic landscape. These innovative drugs inhibit the complement system, which plays a central role in the pathophysiology of PNH. The development and approval of these complement inhibitors have provided patients with the first disease-specific treatments, substantially improving clinical outcomes.
Several companies have made their mark in the PNH drug market, with a strong focus on research and development for more effective and patient-friendly treatments. Leading players include Alexion Pharmaceuticals, Inc., which developed eculizumab, a monoclonal antibody that has been a cornerstone in PNH treatment. Other notable companies operating in the space are Apellis Pharmaceuticals, which has made strides with its complement inhibitor pegcetacoplan, and Novartis, exploring gene-therapy approaches to provide long-term relief for patients afflicted by the disorder. These companies, along with others engaged in the Show Less Read more